Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIT-001 for Prevention of Oral Mucositis in HNSCC
NCT04651634Phase 2Active, not recruiting
- Sponsor
- MitoImmune Therapeutics
- Start
- Jun 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of LC28-0126 in oral mucositis (OM), sponsored by MitoImmune Therapeutics. Started Jun 2021; status: active, not recruiting.
02
Drugs
LC28-0126
03
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT04651634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04651634.